Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy

Vladimir Yutkin, Hashim U. Ahmed, Ian Donaldson, Neil McCartan, Khurram Siddiqui, Mark Emberton, Joseph L. Chin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer.

Patients and Methods Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed.

Results Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population.

Conclusion In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.

Original languageEnglish
Pages (from-to)1157-1162
Number of pages6
JournalUrology
Volume84
Issue number5
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Brachytherapy
Prostatic Neoplasms
Dysuria
Recurrence
Population Characteristics
Prostate-Specific Antigen
Fistula
Canada
Survival Rate

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy. / Yutkin, Vladimir; Ahmed, Hashim U.; Donaldson, Ian; McCartan, Neil; Siddiqui, Khurram; Emberton, Mark; Chin, Joseph L.

In: Urology, Vol. 84, No. 5, 01.11.2014, p. 1157-1162.

Research output: Contribution to journalArticle

Yutkin, V, Ahmed, HU, Donaldson, I, McCartan, N, Siddiqui, K, Emberton, M & Chin, JL 2014, 'Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy', Urology, vol. 84, no. 5, pp. 1157-1162. https://doi.org/10.1016/j.urology.2014.06.054
Yutkin, Vladimir ; Ahmed, Hashim U. ; Donaldson, Ian ; McCartan, Neil ; Siddiqui, Khurram ; Emberton, Mark ; Chin, Joseph L. / Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy. In: Urology. 2014 ; Vol. 84, No. 5. pp. 1157-1162.
@article{bfdc7bb470904082b83a0cf0bd31ca00,
title = "Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy",
abstract = "Objective To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer.Patients and Methods Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed.Results Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4{\%}. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7{\%} and 73.3{\%} using the {"}nadir prostate-specific antigen level{"} +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population.Conclusion In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.",
author = "Vladimir Yutkin and Ahmed, {Hashim U.} and Ian Donaldson and Neil McCartan and Khurram Siddiqui and Mark Emberton and Chin, {Joseph L.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.urology.2014.06.054",
language = "English",
volume = "84",
pages = "1157--1162",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy

AU - Yutkin, Vladimir

AU - Ahmed, Hashim U.

AU - Donaldson, Ian

AU - McCartan, Neil

AU - Siddiqui, Khurram

AU - Emberton, Mark

AU - Chin, Joseph L.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer.Patients and Methods Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed.Results Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population.Conclusion In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.

AB - Objective To report our experience with salvage high-intensity focused ultrasound (HIFU) in patients with local failure after brachytherapy for prostate cancer.Patients and Methods Whole-gland HIFU was administered to prospectively recruited patients with local histologic failure after brachytherapy at 2 institutions in the United Kingdom and Canada. Functional and oncologic outcomes of the procedure were analyzed.Results Nineteen patients underwent the treatment, 12 with Gleason sum 7 and 5 with Gleason sum 8 at recurrence. Thirteen men had grade-3a or -3b complications by the Clavien system; there were no grade-4 or -5 complications. The most common postoperative complication was dysuria, which was self-limited. Three men developed rectourethral fistulae. The overall continence rate was 68.4%. At a mean follow-up of 51.6 months, all men were alive. The overall biochemical recurrence-free survival rate was 66.7% and 73.3% using the "nadir prostate-specific antigen level" +1.3 ng/mL and +2 mg/ml criteria, respectively. This study is limited by the small cohort size, relatively short follow-up period, and heterogeneity of the patient population.Conclusion In this, the largest prospective series to date, we demonstrate that salvage HIFU for locally recurrent prostate cancer after failed primary brachytherapy has encouraging disease control results, albeit with a relatively high complication rate.

UR - http://www.scopus.com/inward/record.url?scp=84908339878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908339878&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2014.06.054

DO - 10.1016/j.urology.2014.06.054

M3 - Article

VL - 84

SP - 1157

EP - 1162

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -